ATIF Holdings Limited (NASDAQ:ATIF, the ", Company", or ", ATIF", )))) announces that its subsidiary, ATIF Business Management LLC, has entered into a services agreement with Genehope Holdings and, pursuant to the terms
Proceeds to fund company's clinical trials, commercial product launch, and working capitalInitial conversion price set at $1.50 per shareSAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ:AIMD,
LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern's AI Platform, RADR®, as a potential therapy for a wide range of advanced solid tumors.LP-184 is
Pseudonymous analyst Rekt Capital on Saturday shared observations on Dogecoin’s (CRYPTO: DOGE) performance, pointing out a potential bullish divergence.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma multiforme (GBM) tumors.